Compare Biogen Inc (BIIB) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Microsoft — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while Microsoft trades at $500.3 (market cap $3.74T). The key difference: Microsoft is far larger — about 124.1× Biogen Inc's market cap, and Microsoft pays a 0.72% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MSFT | |
|---|---|---|
Market Cap | $30.13B | $3.74T |
Sector | Health | Technology |
52-Week High | $216.63 | $542.07 |
52-Week Low | $128.93 | $352.83 |
Enterprise Value | $37.20B | $3.72T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Recent news highlights Microsoft's AI leadership and Azure growth potential, though concerns about capital expenditures persist. The stock trades near pivot point resistance at $507 with strong support at $500.
Outlook remains positive with 80% analyst buy ratings and $552.73 consensus target offering 9% upside. Key opportunities include AI integration and cloud growth, while risks involve competitive pressures and execution on large capital investments. The combination of strong fundamentals and technical momentum supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
